Drug intelligence / Profile preview

TPQD

Development stage: Preclinical
Lead developer: Telix Pharmaceuticals
Modality: Small Molecules
Administration: Unknown

Overview

TPQD is a novel pharmaceutical compound under development with preliminary data suggesting efficacy in resolving neurological disorders associated with mitochondrial dysfunction. It has shown promise in treating equine protozoal myeloencephalitis (EPM) in horses and similar diseases in companion animals. The compound is being investigated for multiple disease targets relevant to both animal and human health, particularly where current treatments are lacking[1].

Brand names: TPQD
Other names: TPQD

Beyond the preview

Go deeper on TPQD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPQD.

Explore the full profile